학술논문
Syndemic trajectories of heavy drinking, smoking, and depressive symptoms are associated with mortality in women living with HIV in the United States from 1994 to 2017.
Document Type
Academic Journal
Author
Chichetto NE; University of FloridaGainesville, FL32611, USA. Electronic address: nchichetto@ufl.edu.; Gebru NM; Brown UniversityProvidence, RI02912, USA.; Plankey MW; Georgetown University Medical CenterWashington, DC20057, USA.; Tindle HA; Vanderbilt University Medical CenterNashville, TN37232, USA; Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare SystemNashville, TN37212USA.; Koethe JR; Vanderbilt University Medical CenterNashville, TN37232, USA.; Hanna DB; Albert Einstein College of MedicineBronx, NY10461, USA.; Shoptaw S; David Geffen School of Medicine at UCLA, Los Angeles, CA90095USA.; Jones DL; University of Miami Miller School of MedicineMiami, FL33136, USA.; Lazar JM; SUNY-Downstate Medical CenterBrooklyn, NY11203, USA.; Kizer JR; San Francisco Veterans Affairs Health Care System, University of California, San Francisco, CA94121USA.; Cohen MH; Stroger Hospital/Cook County Health and Hospitals SystemChicago, IL60612, USA.; Haberlen SA; Johns Hopkins Bloomberg School of Public HealthBaltimore, MD21205, USA.; Adimora AA; UNC-Chapel Hill, Chapel Hill, NC27599USA.; Lahiri CD; Department of Medicine, Division of Infectious Diseases, Emory UniversityAtlanta, GA30322, USA.; Wise JM; University of Alabama at BirminghamBirmingham, AL35294, USA.; Freiberg MS; Vanderbilt University Medical CenterNashville, TN37232, USA; Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare SystemNashville, TN37212USA.
Source
Publisher: Elsevier Country of Publication: Ireland NLM ID: 7513587 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0046 (Electronic) Linking ISSN: 03768716 NLM ISO Abbreviation: Drug Alcohol Depend Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Heavy drinking, smoking, and depression are common among people with HIV. Little is known about the co-occurring, synergistic effect of having two or more of these conditions long-term -a sustained syndemic - on mortality among women with HIV (WWH).
Methods: Data from 3282 WWH of the Women's Interagency HIV Study from 1994 to 2017 were utilized. National Death Index review identified cause of death (n=616). Sustained syndemic phenotypes were based on membership in high-risk groups defined by group-based trajectory models of repeated self-reported alcohol use, smoking, and depressive symptoms and their co-occurrence. Cox proportional hazard models estimated associations of sustained syndemic phenotypes with all-cause, non-AIDS, and non-overdose mortality, adjusting for age, race/ethnicity, education, enrollment wave, illicit drug use, and time-varying HIV viral load and CD4+ T-cell count.
Results: WWH were 58% Black and 26% Hispanic, with a mean baseline age of 36.7 years. Syndemic phenotypes included zero (45%, n=1463), heavy drinking only (1%, n=35), smoking only (28%, n=928), depressive symptoms only (9%, n=282), and 2+ trajectories (17%, n=574). Compared to zero trajectories, having 2+ trajectories was associated with 3.93 times greater all-cause mortality risk (95% CI 3.07, 5.04) after controlling for confounders and each high-risk trajectory alone. These findings persisted in sensitivity analyses, removing AIDS- and overdose-related mortalities.
Conclusions: Clustering of 2+ conditions of heavy drinking, smoking, and depression affected nearly one in five WWH and was associated with higher mortality than zero or one condition. Our findings underscore the need for coordinated screening and parsimonious treatment strategies for these co-occurring conditions.
Competing Interests: Declaration of Competing Interest Dr. Kizer reports stock ownership in Abbott, Bristol Myers Squibb, Johnson & Johnson, Medtronic, Merck, and Pfizer. Dr. Lahiri receives grant funding from Merck and serves on the Advisory Board for Theratechnologies, Inc. Dr. Adimora has received fees for consulting from Merck and Gilead. Merck and Gilead have provided her institution with funding for her research. Dr Palella has been a consultant or on the Speakers’ Bureau for ViiV, Gilead, Janssen and Merck. None of the other authors had any financial or other conflicts of interest.
(Copyright © 2023 Elsevier B.V. All rights reserved.)
Methods: Data from 3282 WWH of the Women's Interagency HIV Study from 1994 to 2017 were utilized. National Death Index review identified cause of death (n=616). Sustained syndemic phenotypes were based on membership in high-risk groups defined by group-based trajectory models of repeated self-reported alcohol use, smoking, and depressive symptoms and their co-occurrence. Cox proportional hazard models estimated associations of sustained syndemic phenotypes with all-cause, non-AIDS, and non-overdose mortality, adjusting for age, race/ethnicity, education, enrollment wave, illicit drug use, and time-varying HIV viral load and CD4+ T-cell count.
Results: WWH were 58% Black and 26% Hispanic, with a mean baseline age of 36.7 years. Syndemic phenotypes included zero (45%, n=1463), heavy drinking only (1%, n=35), smoking only (28%, n=928), depressive symptoms only (9%, n=282), and 2+ trajectories (17%, n=574). Compared to zero trajectories, having 2+ trajectories was associated with 3.93 times greater all-cause mortality risk (95% CI 3.07, 5.04) after controlling for confounders and each high-risk trajectory alone. These findings persisted in sensitivity analyses, removing AIDS- and overdose-related mortalities.
Conclusions: Clustering of 2+ conditions of heavy drinking, smoking, and depression affected nearly one in five WWH and was associated with higher mortality than zero or one condition. Our findings underscore the need for coordinated screening and parsimonious treatment strategies for these co-occurring conditions.
Competing Interests: Declaration of Competing Interest Dr. Kizer reports stock ownership in Abbott, Bristol Myers Squibb, Johnson & Johnson, Medtronic, Merck, and Pfizer. Dr. Lahiri receives grant funding from Merck and serves on the Advisory Board for Theratechnologies, Inc. Dr. Adimora has received fees for consulting from Merck and Gilead. Merck and Gilead have provided her institution with funding for her research. Dr Palella has been a consultant or on the Speakers’ Bureau for ViiV, Gilead, Janssen and Merck. None of the other authors had any financial or other conflicts of interest.
(Copyright © 2023 Elsevier B.V. All rights reserved.)